Literature DB >> 22297716

Glutamatergic transmission in schizophrenia: from basic research to clinical practice.

Joshua Kantrowitz1, Daniel C Javitt.   

Abstract

PURPOSE OF REVIEW: The past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics. RECENT
FINDINGS: We review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans.
SUMMARY: Although evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297716      PMCID: PMC5224527          DOI: 10.1097/YCO.0b013e32835035b2

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  42 in total

1.  NMDA receptor regulates migration of newly generated neurons in the adult hippocampus via Disrupted-In-Schizophrenia 1 (DISC1).

Authors:  Takashi Namba; Guo-Li Ming; Hongjun Song; Chikako Waga; Atsushi Enomoto; Kozo Kaibuchi; Shinichi Kohsaka; Shigeo Uchino
Journal:  J Neurochem       Date:  2011-05-19       Impact factor: 5.372

2.  Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.

Authors:  L V Kristiansen; B Bakir; V Haroutunian; J H Meador-Woodruff
Journal:  Schizophr Res       Date:  2010-03-29       Impact factor: 4.939

3.  No association between DAO and schizophrenia in a Japanese patient population: a multicenter replication study.

Authors:  Tohru Ohnuma; Nobuto Shibata; Hajime Baba; Kazutaka Ohi; Yuka Yasuda; Yukako Nakamura; Tomo Okochi; Hiroshi Naitoh; Ryota Hashimoto; Nakao Iwata; Norio Ozaki; Masatoshi Takeda; Heii Arai
Journal:  Schizophr Res       Date:  2010-02-23       Impact factor: 4.939

4.  A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.

Authors:  Hsien-Yuan Lane; Ching-Hua Lin; Yu-Jhen Huang; Chun-Hui Liao; Yue-Cune Chang; Guochuan E Tsai
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-04       Impact factor: 5.176

5.  Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation.

Authors:  E A Hackler; N E Byun; C K Jones; J M Williams; R Baheza; S Sengupta; M D Grier; M Avison; P J Conn; J C Gore
Journal:  Neuroscience       Date:  2010-03-27       Impact factor: 3.590

Review 6.  Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

Authors:  John H Krystal; Sanjay J Mathew; D Cyril D'Souza; Amir Garakani; Handan Gunduz-Bruce; Dennis S Charney
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

7.  Effects of low-dose D-serine on recognition and working memory in mice.

Authors:  Patricia Bado; Caroline Madeira; Charles Vargas-Lopes; Thiago C Moulin; Ana Paula Wasilewska-Sampaio; Luise Maretti; Ricardo V de Oliveira; Olavo B Amaral; Rogério Panizzutti
Journal:  Psychopharmacology (Berl)       Date:  2011-05-10       Impact factor: 4.530

Review 8.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

9.  Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants.

Authors:  Sumie Leung; Rodney J Croft; Valérie Guille; Kirsty Scholes; Barry V O'Neill; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2009-12-10       Impact factor: 4.530

10.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

View more
  64 in total

1.  Instant and Lasting Down-Regulation of NR1 Expression in the Hippocampus is Associated Temporally with Antidepressant Activity After Acute Yueju.

Authors:  Baomei Xia; Hailou Zhang; Wenda Xue; Weiwei Tao; Chang Chen; Ruyan Wu; Li Ren; Juanjuan Tang; Haoxin Wu; Baochang Cai; Ravid Doronc; Gang Chen
Journal:  Cell Mol Neurobiol       Date:  2016-01-29       Impact factor: 5.046

Review 2.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

3.  Quantum energy levels of glutamate modulate neural biophotonic signals.

Authors:  Zhengrong Han; Weitai Chai; Zhuo Wang; Fangyan Xiao; Jiapei Dai
Journal:  Photochem Photobiol Sci       Date:  2021-02-26       Impact factor: 3.982

4.  SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors.

Authors:  Jia Cheng; Wenhua Liu; Lara J Duffney; Zhen Yan
Journal:  J Physiol       Date:  2013-06-17       Impact factor: 5.182

5.  An Association Study Between Genetic Polymorphisms in Functional Regions of Five Genes and the Risk of Schizophrenia.

Authors:  Peng Yan; Xiaomeng Qiao; Hua Wu; Fangyuan Yin; Jing Zhang; Yuanyuan Ji; Shuguang Wei; Jianghua Lai
Journal:  J Mol Neurosci       Date:  2016-04-07       Impact factor: 3.444

6.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia.

Authors:  Dan Shan; Daniel Mount; Stephen Moore; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-02-21       Impact factor: 4.939

Review 7.  Wnt signaling: role in Alzheimer disease and schizophrenia.

Authors:  Nibaldo C Inestrosa; Carla Montecinos-Oliva; Marco Fuenzalida
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-18       Impact factor: 4.147

Review 8.  Multimodal functional and structural imaging investigations in psychosis research.

Authors:  C Christoph Schultz; Paolo Fusar-Poli; Gerd Wagner; Kathrin Koch; Claudia Schachtzabel; Oliver Gruber; Heinrich Sauer; Ralf G M Schlösser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-02       Impact factor: 5.270

9.  Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia.

Authors:  Parisa Afshari; Marina Myles-Worsley; Ori S Cohen; Josepha Tiobech; Stephen V Faraone; William Byerley; Frank A Middleton
Journal:  Mol Neuropsychiatry       Date:  2015-07-08

Review 10.  Auditory dysfunction in schizophrenia: integrating clinical and basic features.

Authors:  Daniel C Javitt; Robert A Sweet
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.